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The results of cost-effectiveness illustrate that quetiapine is dominant in 
Russian patients with bipolar disorder who are initiating atypical antipsychotics 
therapy compared with aripiprazole, olanzapine or ziprasidone.  
 
PMH38  
THE COST-EFFECTIVENESS OF QUETIAPINE, ARIPIPRAZOLE OR OLANZAPINE IN 
PATIENTS WITH BIPOLAR DEPRESSION IN THE RUSSIAN FEDERATION  
Kulikov A, Komarov I 
I.M. Sechenov First Moscow State Medical University, Moscow, Russia  
OBJECTIVES: To explore the cost-effectiveness of quetiapine, aripiprazole or 
olanzapine in Russian Federation (RF) patients with bipolar disorder (BPD) 
depression episodes. METHODS: A cost-effectiveness analysis (CEA) was 
developed to estimate the cost-effectiveness of quetiapine compared with 
aripiprazole or olanzapine. CEA was undertaken from RF health care perspective 
using discount rate of 5%. The time horizon of the analysis was ne year for using 
preventive relapse rates and five years for QALY. Direct health care expenses 
associated with bipolar disorder and resulting follow-up costs were calculated 
using general tariff agreement of Russian obligatory insurance system and 
official national statistics. For reference, accepted exchange rate was 1 EUR = 40 
RUB. RESULTS: Taking into account rates of prevented relapse following cost-
effectiveness ratios (CER) were obtained: 156,915 RUB (3,923 EUR) in quetiapine 
group, 429,362 RUB (10,734 EUR) in aripiprazole group and 221,879 RUB (5,547 
EUR) in olanzapine group. Using QALY values CER were accounted for: 185,236 
RUB (4,631 EUR) in quetiapine group, 478,433 RUB (11,961 EUR) in aripiprazole 
group and 254,100 RUB (6,353 EUR) in olanzapine group. CONCLUSIONS: 
Quetiapine in the treatment of BPD depression episodes is a dominant compared 
with aripiprazole or olanzapine.  
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COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT 
OF RELAPSE PREVENTION FOR BIPOLAR DISORDER: THE RUSSIAN PERSPECTIVE  
Kulikov A, Komarov I 
I.M. Sechenov First Moscow State Medical University, Moscow, Russia  
OBJECTIVES: To assess the efficiency of the atypical antipsychotics used to 
reduce relapses in bipolar disorder, taking into account costs and effectiveness 
(measured as QALY). METHODS: The Russian health care system perspective and 
a 5 year temporal horizon have been used. An annual discount rate assumed was 
of 5%. Taking into account the last literature review on bipolar disorder, four 
fundamental aspects related with bipolar disorder management were analyzed: 
relapse rates, inpatient treatment, outpatient treatment and hospitalization 
rates. The health care direct costs corresponding to the drug acquisition costs 
have been analyzed together with the costs of inpatient diagnostics, costs of 
inpatient treatment and costs of hospitality relapses (stay and drug cost) 
updated with data from Russian health care system. RESULTS: Quetiapine or 
risperidone treatment presents the lower total costs (€13,562 and €13,097 
respectively) compared with the other strategies (aripiprazole = €36,328 and 
olanzapine = €19,957). Quetiapine presents the higher efficacy (QALY) compared 
with the alternatives (quetiapine = 3.551, risperidone = 3.534, aripiprazole = 3.528 
and olanzapine = 3.525). With these results one can emphasize that quetiapine 
or risperidone treatment is dominant with the cost-effectiveness ratio (CER) of 
3819 and 3706, respectively, versus aripiprazole or olanzapine groups (CER 10,297 
and 5,662 respectively). The incremental CER (quetiapine vs. risperidone) is 
€27,322 per QALY. CONCLUSIONS: The results of cost-effectiveness illustrate 
that quetiapine is dominant compared with aripiprazole or olanzapine. Also 
quetiapine therapy is within willingness to pay threshold in case of risperidone 
substitution in Russian patients with bipolar disorder who are initiating atypical 
antipsychotics therapy.  
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ONCE-A-DAY EXTENDED-RELEASE VERSUS TWO-TIMES-DAILY IMMEDIATE-
RELEASE METHYLPHENIDATE FOR THE TREATMENT OF ADHD - A COST 
MINIMIZATION STUDY  
Kachru N1, Sansgiry SS2 
1University of Houston, College of Pharmacy, Houston, TX, USA, 2University of Houston, 
Houston, TX, USA  
OBJECTIVES: Attention Deficit/Hyperactivity Disorder (ADHD) is a 
neurobehavioral disorder and one of the most prevalent chronic health problems 
affecting school-age children, representing a costly major public health problem. 
Keeping in view, the substantial economic burden, the objective of this study 
was to conduct a cost-minimization analysis of once-a-day extended-release (ER) 
versus two-times-daily immediate-release (IR) methylphenidate for the 
treatment of ADHD patients. METHODS: Major literature databases were 
systematically searched to identify appropriate randomized clinical trials and 
meta-analyses to obtain costs associated with both the alternative formulations 
from a payers (third party) perspective. Medical costs included cost of drug, cost 
of assessments, cost of non-compliance, cost of injuries/accidents and cost of in-
school administration and were obtained from published literature. All costs 
were adjusted to 2012 USD using consumer price index. The expected outcome 
was considered to be the same for both the formulations and a cost 
minimization analysis was performed using a decision tree approach. Multiple 
one-way sensitivity analyses were performed on all cost variables to evaluate the 
robustness of the results. RESULTS: The ER regimen of methylphenidate resulted 
in a total annual cost of $4685 per patient which was less costly as compared to 
the IR regimen that resulted in a total annual cost of $9524 per patient for the 
treatment of ADHD. One-way sensitivity analyses results were consistent. 
CONCLUSIONS: In our study Methylphenidate ER had 50.81% less annual 
economic burden as compared to the IR regimen for the treatment of ADHD 
patients.  
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COST-UTILITY OF TWO SHORT-TERM PSYCHOTHERAPIES IN THE  
TREATMENT OF DEPRESSIVE AND ANXIETY DISORDERS DURING  
A THREE-YEAR FOLLOW-UP  
Maljanen T1, Härkänen T2, Virtala E2, Lindfors O2, Tillman P3, Knekt P2 
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OBJECTIVES: Different types of psychotherapy, alone or together with 
pharmaceuticals, are used extensively in the treatment of depressive and 
anxiety disorders. However, only a few studies thus far have addressed the cost-
utility of different psychotherapies. The aim of this study is to compare the 
direct health care costs and the quality of life of persons who have suffered from 
depression or anxiety and have been treated either with short-term 
psychodynamic psychotherapy (SPP) or solution-focused therapy (SFT). The 
follow-up period was three years. METHODS: A total of 198 outpatients aged 20–
45 years suffering from mood or anxiety disorder were randomized to SPP or SFT. 
Patients’ quality of life was assessed using Chubon’s Life Situation Survey (LSS). 
The assessments took place at baseline and at 7, 12 and 36 months after the start 
of the therapy. All direct costs due to mental health problems incurred during 
the three-year follow-up period were taken into account in the analysis. 
RESULTS: During the first 7 months patients’ quality of life improved 
considerably, with mean LSS scores increasing from about 79 to about 93 in both 
groups. This change was also statistically significant. After the 7th month some 
minor improvements continued to be observed in quality of life. At the end of 
the follow-up period the mean LSS scores were in both groups somewhat below 
100, a threshold for very good life quality. The differences between the two 
groups were very small at every measurement point and not statistically 
significant. The direct costs were about equal in both groups. The small positive 
changes observed in the quality of life after the 7th month were at least partly 
due to auxiliary treatments whose costs were much higher than the costs of SPP 
or SFT. CONCLUSIONS: There is little appreciable difference in cost-utility 
between SPP and SFT.  
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OBJECTIVES: To report health care and social service costs from a trial of 
nonpharmacologic depression support program in older African Americans, Beat 
the Blues (BTB). METHODS: Two-group randomized design in which the BTB 
group received the program and the control group did not receive the program. 
BTB employed licensed senior center social workers to meet with participants 
(up to 10 sessions). Components of BTB were depression education, care 
management, stress reduction, referrals and linkages, and behavioral activation. 
Both groups were followed for 4 months. Service use and costs at each time point 
included health care use for depression (outpatient calls and visits to physician, 
emergency department visits, hospitalizations), medications, alternative 
approaches to managing depression (massage, acupuncture), paid caregiving 
(homemaker, home health aide, and visiting nurse), and social services (meals, 
transportation, and social worker support). RESULTS: A total of 129 subjects were 
randomized (68 BTB, 61 wait-list control); the average age was 68.3 years, most 
were female (77.9%), not married (90.4%), not employed (92%), and had an 
average of 6.4 health conditions (range 1-19). In both groups, costs for health care 
use for depression and alternative approaches to managing depression were 
similar at baseline. Medication costs for BTB decreased from $210 at baseline to 
$159 at 4 months, whereas in the wait-list control group, medication costs 
remained roughly constant ($186 at baseline and $197 at 4 months). Both groups 
experienced a decrease in paid caregiving costs ($69 in the BTB group vs. $39 in 
the wait-list control group). The BTB group experienced an overall cost decrease 
of $112 versus $19 in the wait-list control group over the 4 months. 
CONCLUSIONS: Decreases in medication and caregiving costs resulted in a net 
lower cost in the BTB group during observation period. Larger scale translational 
studies are needed to understand the extent to which BTB influences specific 
types of costs.  
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REDUCING SCHIZOPHRENIA ILLNESS RELAPSE  
Furiak N1, Klein RW1, Gahn JC1, Camper SB2, Summers K3 
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Endo Pharmaceuticals Inc., Chadds Ford, 
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OBJECTIVES: To quantify the direct medical resources used and the 
corresponding burden of disease in the treatment of patients with 
schizophrenia. Because low-frequency administration (LFA) of risperidone 
guarantees adherence during treatment intervals and offers fewer opportunities 
to discontinue, adherence and persistence were assumed to improve, thereby 
reducing relapses of major symptoms. METHODS: A decision tree model 
including Markov processes with monthly cycles and a five-year maximum 
timeframe was constructed. Costs were adapted from the literature and 
discounted at a 3% annual rate. The population is a demographically 
homogeneous cohort of patients with schizophrenia, differentiated by initial 
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disease severity (mildly ill, moderately ill, and severely ill). Treatment 
parameters are estimated using published information for once-daily risperidone 
standard oral therapy (RIS-SOT) and once-monthly risperidone long-acting 
injection (RIS-LAI) with LFA therapy characteristics derived from observed study 
trends. One-year and five-year results are expressed as discounted direct 
medical costs and mean number of relapses per patient (inpatient, outpatient, 
total) and are estimated for LFA therapies given at three, six, and nine month 
intervals. RESULTS: The one-year results show that LFA therapy every 3 months 
(LFA-3) ($6,088) is less costly than either RIS-SOT ($10,721) or RIS-LAI ($9,450) 
with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 
versus RIS-SOT versus RIS LAI therapy will reduce costly inpatient relapses (0.16 
vs. 0.51 vs. 0.41). Extending the interval to six (LFA-6) and nine (LFA-9) months 
resulted in further reductions in relapse and costs. Limitations include the fact 
that LFA therapeutic options are hypothetical and do not yet exist and limited 
applicability to compare one antipsychotic agent versus another as only 
risperidone therapy is evaluated. CONCLUSIONS: These study results have 
quantified the potential health state improvements and potential direct medical 
cost savings achievable with the development and use of LFA medication 
delivery technologies.  
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1University of Szeged, Szeged, Hungary, 2University of Pécs, Pécs, Hungary  
OBJECTIVES: To examine the circumstances of the recognition of the autism, the 
problems in connection with the condition of the child as well as the 
opportunities, deficiencies of the support. METHODS: During the research as the 
first step the Autistic Association and its member organizations were selected. 
As the second step the families were reached through them. A total of 358 postal 
examinational questionnaires were sent; the interviewers visited 312 families. 
During my analysis the data of the samples between year 0-18 were used (276 
people). The process of the data was completed by SPSS program. RESULTS: The 
first symptoms of autism are perceived foremost by the parents that is followed 
by an at least 2 years period till the diagnosis. Only 30% of the children speak 
well, only 59% of the parents always understand them. The 38% of children have 
slight or severe insomnia. A total of 84% of the children have frequent or 
permanent behavioural disorders. Due to the child’s autism the families are 
isolated; 40% of the parents have been unemployed since the birth of their child. 
The assistance or communication between the concerned families is incidental 
(5%). The 36% of the parents experienced discrimination in the field of health 
care. The care of people with disabilities lacks from the health visitors’ graduate 
training that makes early recognition and the care more difficult. 
CONCLUSIONS: There is no comprehensive strategy in Hungary for the solution 
of the problems of the families raising autistic children. Developing a filtering 
system is necessary which would decrease the time span between the 
recognition and the diagnose. Our other goal is to build a comprehensive training 
system to broaden the knowledge of the health professionals.  
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PATIENT'S REPORTED OUTCOMES WITH THE USE OF NALMEFENE  
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OBJECTIVES: To evaluate the impact on alcohol-dependent patients’ reported 
outcomes (PROs) from the as-needed use of nalmefene versus placebo in 
reduction of alcohol consumption. METHODS: Two 6-month randomized, 
double-blind, placebo-controlled, efficacy studies assessing nalmefene 18mg 
(base) were conducted in Europe (ESENSE 1 [NCT00811720]; ESENSE 2 
[NCT00812461]). All patients took part in a motivational intervention (BRENDA) to 
support behavioural change and adherence to treatment. The Short Form Health 
Survey (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Drinker Inventory of 
Consequences (DrInC-2R) questionnaires were administered at baseline, weeks 
12 and 24. Post-hoc analyses of the pooled subgroup of patients with a high 
drinking risk level (men:>60 g/day; women:>40 g/day) assessed change from 
baseline using mixed models repeated measures. RESULTS: At baseline, the 
sample comprised 641 patients: 322 in the placebo group, 319 in the nalmefene 
group. The SF-36 Mental Component Score (MCS) and the EQ-5D health state 
score were 40.9±12.6 and 67.9±17.2 in the placebo group; 40.9±11.9 and 68.9±17.7 
in the nalmefene group. The MCS improvement at week 24 was significantly 
correlated to HDD (Heavy Drinking Day) and TAC (Total Alcohol Consumption) 
reduction and was significantly larger for the nalmefene group compared to 
placebo (p=0.0008): the means change from baseline were 5.74±0.79 and 2.65±0.78 
in the nalmefene and placebo groups respectively. For the EQ-5D, the mean 
change from baseline for nalmefene compared to placebo for the health state 
score and the utility index score was 3.46 (p=0.0124) and 0.03 points (p=0.0445) 
respectively. The mean DrInC-2R total score change from baseline to week 24 
was significantly correlated to HDD and TAC reduction. The improvement, 
indicating less alcohol-related problems, was significantly larger with nalmefene 
(17.86±1.31) than for placebo (14.64±1.30) (p=0.0292). CONCLUSIONS: As-needed 
use of nalmefene for reduction of alcohol consumption leads to statistically 




QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF THE 
SYMPTOMS OF MAJOR DEPRESSIVE DISORDER (S-MDD), A CONSORTIUM-
DEVELOPED PATIENT REPORTED OUTCOME MEASURE  
McCarrier KP1, Martin ML1, Bushnell DM1, Abraham L2, Bush EN3, Houle CR4, Mathews M5, 
Carpenter LL6, Blum SI5 
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5Forest Research Institute, Jersey City, NJ, USA, 6Brown University, Providence, RI, USA  
OBJECTIVES: Complete qualitative concept elicitation (CE) and cognitive 
interviews leading to preliminary development of a patient-reported outcome 
(PRO) measure to assess treatment benefit in major depressive disorder (MDD) 
clinical trials. METHODS: Qualitative interviews were conducted with adult MDD 
patients in the US who recently experienced a major depressive event. All 
participants had a Hamilton Depression Rating Scale (HAM-D) total score >18 at 
screening. Experienced interviewers conducted CE and cognitive interview 
sessions using semi-structured interview guides. The CE interview guide was 
used to elicit spontaneous reports of symptom experiences along with probing to 
further explore and confirm concepts. The cognitive interview guide was 
developed to evaluate concept relevance, understandability, and structure of the 
draft items, and to facilitate further instrument refinement. All interview 
sessions were audio recorded and transcribed. The CE interviews were coded for 
qualitative content analysis using Atlas.ti, and the cognitive interview 
transcripts were summarized in cognitive report tables. RESULTS: Forty patients 
[mean age: 46.2; 67.5% female; 45.0% white (non-Hispanic)] participated in the CE 
interviews. Mean (SD) HAM-D total score of the participants was 24.4 (4.3). A total 
of 3,022 symptom codes, representing 91 different concepts were derived from 
the transcripts. Data from the CE interviews was considered alongside existing 
literature and clinical expert opinion during an item-generation meeting, leading 
to development of a 36-item measure with a 5-point response scale. 
Subsequently, fifteen patients participated in three waves of cognitive 
interviews, during which, one item was removed and four others were modified. 
CONCLUSIONS: The S-MDD is a 35-item PRO measure intended for use as an 
endpoint in MDD clinical trials to support medical product labeling. It was 
developed in accordance with the FDAs PRO Guidance and best practices. 
Qualitative interviews have provided evidence for content validity. Future 
quantitative studies will confirm the S-MDD’s measurement properties and 
support FDA qualification.  
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Citalopram (Celexa®) is in the selective serotonin reuptake inhibitor (SSRI) class 
of antidepressants. It is taken orally. Citalopram has been linked to both QT 
prolongation and Torsade de pointes (TdP), and these risks may be dose related. 
OBJECTIVES: To analyze the association between QT prolongation and TdP 
adverse events and the utilization of citalopram and other SSRIs. METHODS: 
This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting 
System (FAERS) database. The database included 7,840,225 adverse events 
associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The 
number of reported QT-prolongation and TdP cases associated with each study 
drug was calculated over time. Furthermore, for each case, dosage of the drug, 
when available in the report, was noted. RESULTS: A total of 1192 reported cases 
of QT prolongation and TdP were associated with SSRI drugs over the 14-year 
study period. Only 18% (219) of the adverse event reports were related 
specifically to citalopram, while the rest were related to other SSRI drugs. There 
were 911 reports for women, 252 for men, and 29 reports without gender 
information. The rate of QT prolongation and TdP associated with dosages of 20 
mg, 40 mg, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. 
However, the percentage of reports without dosage information was 37%, so we 
were unable to draw any conclusions regarding dosage-related events. 
CONCLUSIONS: The results confirmed an association between the use of 
citalopram with QT prolongation and TdP. Furthermore, the association was not 
limited to citalopram alone but was widespread across the SSRIs. There were 
more adverse events observed for women than for men. Dose dependency was 
not established in this study. Future studies are warranted.  
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USING TRANSLATABILITY ASSESSMENT TO REFINE A PATIENT- REPORTED 
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OBJECTIVES: To show how translatability assessment during the patient-
reported outcome (PRO) measure development process can be used to identify 
areas where wording changes are needed to improve and refine the measure. 
METHODS: A translatability assessment was conducted on a new 35-item PRO 
measure called Symptoms of Major Depressive Disorder (S-MDD) for evaluating 
treatment benefits in MDD. Five different languages were selected (French, 
Spanish, German, Chinese, and Russian). Each PRO item was reviewed and 
assigned a difficulty rating between 1 (no difficulty) and 5 (extreme difficulty) by 
an experienced translation consultant in each language. The difficult concepts 
for translation were compared to the problematic items for patient 
comprehension (from cognitive interviews) to identify difficult items for both 
translation and patient comprehension. RESULTS: Three items of the 35-item S-
MDD showed difficulty in patient comprehension and in the ability to accurately 
translate the concept. Due to the convergence of these two problematic findings 
during the PRO development, the item “how difficult was it for you to keep your 
mind free of worrying thoughts?” was changed to “how difficult was it for you to 
